David Lewis

Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial

Sonya Abraham, Helene Bæk Juel, Peter Fibiger Bang et al. · The Lancet Infectious Diseases · 2019 · 190 citations

Vaccination, Mucosal Vaccination, Caf01 Liposomes +4

Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial

Frances Priddy, David Lewis, Hana Hassanin et al. · The Lancet HIV · 2019 · 126 citations · Full text

Safety Profile and Immunologic Responses of a Novel Vaccine Against Shigella sonnei Administered Intramuscularly, Intradermally and Intranasally: Results From Two Parallel Randomized Phase 1 Clinical Studies in Healthy Adult Volunteers in Europe

Odile Launay, David Lewis, Alessandra Anemona et al. · EBioMedicine · 2017 · 110 citations · Full text

Early Rise of Blood T Follicular Helper Cell Subsets and Baseline Immunity as Predictors of Persisting Late Functional Antibody Responses to Vaccination in Humans

Fabiana Spensieri, Emilio Siena, Erica Borgogni et al. · PLoS ONE · 2016 · 49 citations · Full text

Adaptive Immune System, Humoral Response, Immunology +17

Identification of potential biomarkers of vaccine inflammation in mice

Paul F. McKay, Deniz Cizmeci, Yoann Aldon et al. · eLife · 2019 · 39 citations · Full text

Immunology, Potential Biomarkers, Immunotherapy +16